Summary
MDM2 was transfected to acute lymphoblastic leukemia (ALL) line EU-4 cell which lacks P53 expression and expresses very low levels of MDM2. The results showed that MDM2 upregulated P65 expression in mRNA level and protein level. The effect of adriamycin (ADM) on MDM2-transfected EU-4 cell was detected by MTT assay. It was found that MDM2 transfection could increase drug resistance of EU-4 cells to ADM as compared with parent cells. Since the expression of E-selectin is P65 dependent, E-selectin promoter-CAT construct and P65 and MDM2 expression plasmids were co-transfected to EU-4 cells, revealing that MDM2 increased P65-mediated transactivation of E-selectin promoter. In the absence of P65, MDM2 had no effect on the transactivation of E-selectin. Moreover, MDM2 antisense couldn’t change the transactivation of E-selectin. It was concluded that MDM2 could up-regulate transcriptionally P65 expression; MDM2 increased drug resistance of leukemia cells to ADM; MDM2 elevated NF-kappaB activity in a P53-independent manner.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sigalas I, Calvert A H, Anderson J Jet al. Alternatively spliced mdm2 transcripts with loss of P53 binding domain sequence: Transforming ability and frequent detection in human cancer. Nat Med, 1996, 2:912
Martin K, Trouche D, Hagenmeier Cet al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 1995, 375:691
Xiao Z X, Chen J, Levine A Jet al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 1995, 375:694
Ghosh S, May M J, Kopp E B. NFKB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 1998, 16:225
Zhou M, Yeager A M, Smith S Det al. Overexpression of MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type P53 gene. Blood, 1995, 85:1608
Zhou M, Gu L, Abshire T Cet al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia, 2000, 14:61
Sonenshein G E. Rel/NFKB transcription factors and the control of apoptosis. Cancer Biology, 1997, 8:113
Suzuki A, Toi M, Yamamoto Yet al. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res, 1998, 89:221
Moller M B, Nielson O, Pesersen N T. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct Non-Hodgkin’s lymphoma entities. Mod Pathol, 1999, 12:1010
Taubert H, Koehler T, Meye Aet al. MDM2 mRNA level is a prognositic factor in soft tissue sarcoma. Mol Med, 2000, 6:50
Author information
Authors and Affiliations
Additional information
HU Qun, female, born in 1962, Associate Professor
This project was supported by a grant from National Natural Sciences Foundation of China (No. 39970778).
Rights and permissions
About this article
Cite this article
Qun, H., Muxiang, Z., Shuangyou, L. et al. Regulation of NFκB/P65 by MDM2 in pediatric acute lymphoblastic leukemia. Current Medical Science 23, 68–70 (2003). https://doi.org/10.1007/BF02829468
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02829468